Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection

Inclusion Criteria: * Age greater than or equal to 18 years of age * Ability to understand and sign informed consent * Biopsy-proven diagnosis of previous cancer (solid or hematologic disease) * Participants must be diagnosed with active malignancy, defined as the presence of metastatic disease; or patient undergoing curative treatment during cancer treatment, regardless of the therapeutic modality. * Confirmed diagnosis of COVID-19 by the presence of a positive PCR test or positive serological test and / or diagnosis presumed by the presence of flu-like symptoms associated to suggestive findings on CT scan. * ECOG performance status 0 to 2 * Patients must have an assessment of adequate organ function within 28 days prior to enrollment, evidenced by: * Hemoglobin ≥ 9.0 g / dL * Leukometry\> 2,000 / mm3 * Absolute neutrophil count ≥ 1,500 / mm3 * Platelet count ≥ 100,000 / mm3 * Creatinine clearance ≥ 30 mL / min. Creatinine clearance (CrCl) should be calculated according to the Cockcroft-Gault formula. * Total bilirubin \<3 x the upper limit of normal (ULN), except for patients with known Gilbert's syndrome. * Aspartate aminotransaminase (AST) \<3.0 x LSN. * Alanine aminotransaminase (ALT) \<3.0 x ULN. Exclusion Criteria: * Currently taking an angiotensin converting enzyme inhibitor (ACEi) or Angiotensin receptor blocker (ARB). * Patients who presents with severe conditions at the time of diagnosis requiring ICU admission. * Prior reaction or intolerance to an ARB or ACE inhibitor. * Blood pressure less than 110/70 mmHg at presentation * Potassium greater than 5.0 mEq / L * Pregnancy or breastfeeding * Prior reaction to Ivermectin. * Patient currently enrolled in another research protocol